DAN STEINFINK: Open Payments
NPI 1144295296 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,158 in 53 payments from 15 companies in 2025. Trend: 2023 $1,556 · 2024 $1,708 · 2025 $1,158
Food & beverage: $1,130Education: $27
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $162 |
| Otsuka America Pharmaceutical, Inc. | 9 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $148 |
| E.R. Squibb & Sons, L.L.C. | 6 | $115 |
| ABBVIE INC. | 4 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $109 |
| Lundbeck LLC | 3 | $62 |
| Corium, LLC | 2 | $61 |
| Eisai Inc. | 2 | $59 |
| Axsome Therapeutics, Inc. | 2 | $43 |
Products named: REXULTI, INGREZZA, CAPLYTA, COBENFY, VRAYLAR, TRINTELLIX, Azstarys, Leqembi.
Industry payments across TX — which companies pay providers there.
